Hematopoietic stem cell (HCT) transplantation offers curative therapy for a variety of malignant and nonmalignant disorders. It is limited by donor availability, transplant related toxicity, graft versus host disease, relapse of malignancy, infections, and for some patients, reduction in post-transplant quality of life. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) was established in 2001 to develop and execute scientifically meritorious, prospective clinical trials to address these issues. The Network has launched >20 trials with the support of a Data and Coordinating Center (DCC) comprised of a Consortium of the Center for International Blood and Marrow Transplant Research, the National Marrow Donor Program and The EMMES Corporation. The members of this DCC Consortium propose to continue supporting the Network and managing the efficient development, implementation and completion of high-quality Phase l-lll clinical trials for the Network, including concept evaluation and prioritization, protocol development with appropriate statistical designs, timely activation and accrual, monitoring for safety, compliance and data accuracy, and analyzing and disseminating results. The DCC Consortium will coordinate and support all BMT CTN activities maintaining a state-of-the-art database and systems for acquisition and storage of biologic specimens, ensuring data quality, laboratory compliance and adherence to regulatory requirements, managing contractual arrangements and fiscal activities, monitoring and improving center and overall Network performance and supporting all Network committees and activities with meeting planning and other logistical support. The Consortium will also help amplify and leverage Network resources through collaboration with other scientific bodies including National Cancer Institute-funded Cancer Cooperative Groups and the Stem Cell Therapeutic Outcomes Database to maximize successful completion of high quality and high priority clinical trials in HCT.
The proposed Data and Coordinating Center (DCC) will support all activities of the BMT CTN, using the extensive expertise of the investigators in clinical research and transplantation. We will take advantage of collaborations with other organizations and initiatives to maximize efficiency and trial participation. The goal is to complete high quality clinical trials that focus on the most important barriers to transplant success.
|Stroncek, David F; Shaw, Bronwen E; Logan, Brent R et al. (2018) Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. Biol Blood Marrow Transplant 24:175-184|
|Khera, Nandita; Mau, Lih-Wen; Denzen, Ellen M et al. (2018) Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization. Biol Blood Marrow Transplant 24:2204-2210|
|Martens, Michael J; Logan, Brent R (2018) A group sequential test for treatment effect based on the Fine-Gray model. Biometrics 74:1006-1013|
|Buchbinder, David; Kelly, Debra Lynch; Duarte, Rafael F et al. (2018) Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant 53:535-555|
|William, Basem M; Wang, Tao; Haagenson, Michael D et al. (2018) Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 24:827-831|
|Qayed, Muna; Wang, Tao; Hemmer, Michael T et al. (2018) Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant 24:521-528|
|Harris, Andrew C; Boelens, Jaap J; Ahn, Kwang Woo et al. (2018) Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv 2:1198-1206|
|Chhabra, Saurabh; Ahn, Kwang Woo; Hu, Zhen-Huan et al. (2018) Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv 2:2922-2936|
|Radivoyevitch, Tomas; Dean, Robert M; Shaw, Bronwen E et al. (2018) Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. Leuk Res 74:130-136|
|Allen, Carl E; Marsh, Rebecca; Dawson, Peter et al. (2018) Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood 132:1438-1451|
Showing the most recent 10 out of 230 publications